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m 
Abstract tH NMR methods are described which allow direct 
studies of the Cys 34 binding site of albumin in intact human blood 
plasma in vitro. Antiarthritic gold drugs and the alcohol-aversive 
drug disulfiram induce a structural transition detectable via Hel  
and H~2 resonances of His 3 of albumin, and reactions of cystine, 
glutathione and captopril in plasma have also been investigated. 
Contrary to most assumptions, little of the albumin in normal 
plasma appears to be blocked at Cys ~ as a cystine disulfide. 
K, V words." Blood plasma; Albumin; ~H NMR;  Gold drug; 
D~sulfide; Thiol 
I. Introduction 
Mbumin (66.5 kDa) is a non-glycosylated, single-chain pro- 
te~ a of 585 amino acids with 17 disulphide bridges and one free 
th~ol at Cys34; with a concentration i blood of ca. 0.63 raM. 
It s the major transport protein in blood plasma for drugs, as 
well as for fatty acids, hormones, metal ions and xenobiotics 
[1.2]. However, the structural and dynamic interactions of these 
substances with albumin are, in general, poorly understood and 
th~s is hampering the rational design of many drugs and diag- 
ne~tic agents [3]. 
'¢,trong binding sites on albumin include: I and II for small 
organic molecules, III and IV for long-chain fatty acids, V 
C.~ s 34, and VI the square-planar N-terminal Cu 2÷ and Ni z+ site 
[4.5]. X-Ray crystallographic studies have recently elucidated 
th~ selectivity of sites I (e.g. for warfarin) and II (e.g. for 
di,~zapam, digitoxin) in subdomains I IA and IIIA, respectively, 
a~,l detected movements of helices when fatty acids bind in sites 
II] and IV. Albumin has not been crystallized with site VI 
occupied, but this metal site has been characterized in solution 
[6] and in model peptides [7]. In contrast, binding and redox 
processes at site V, Cys 34, are much less well characterized 
de,~pite intense interest over many years (e.g. [8]). In the crystal 
stJ acture of albumin, Cys 34 is protected in a crevice where it 
inIeracts with other side-chains, probably His 39 and Glu 82 [5]. 
Tt~is may allow stabilization of the deprotonated thiol and 
account for its low pKa of between 5 and 7 [9,10]. 
We report here that redox chemistry (including disulfide in- 
terchange reactions) and drug binding at site V (Cys 34) can be 
delected irectly in human blood plasma in vitro by ~H NMR 
spectroscopy. It is proposed that binding to this site may be 
accompanied by a 'flip-out' of Cys 34. Although it is often 
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assumed that 3040% of albumin molecules in circulation have 
Cys 34 blocked as a disulfide [11], our experiments suggest hat 
little of the albumin in fresh normal plasma is present in this 
form. The NMR approach reported here should find wide- 
spread application in studies of the redox balance in blood 
plasma and the design of novel drugs and other agents. 
2. Materials and methods 
2. l. Materials" 
L-Cystine, disulfiram (N,N-diethyldithiocarbamate disulfide), gluta- 
thione (y-c-Glu-c-Cys-Gly) disulfide and captopril (D-3-mercapto-2- 
methylpropanoyl-c-proline) w re purchased from Sigma. Auranofin 
(triethylphosphine-(2,3,4,6-tetra- O-acetyl- 1thio-fl-D-glucopyrano-sato- 
S)gold(I)) and aurothiomalate (disodium gold(I) thiomalate) were the 
gifts of SmithKline Beecham and Rh6ne Poulenc, respectively. These 
were added to plasma as aliquots of concentrated aqueous olutions, 
except for auranofin which was added in methanol. 
2.2. Sample preparations 
Blood from a healthy male volunteer was collected into lithium hep- 
arin vials and centrifuged at 277 K to remove cells, and then treated 
in one of two ways. For samples in 95% H2O15% DzO, 50/11 of 0.2 M 
NaH2PO4 (in DzO) was added to 0.95 ml of plasma, whereas for work 
with D20 samples, plasma was freeze-dried immediately in 0.5 ml ali- 
quots and reconstituted in half the original volume of NaH2PO4 (10 
mM) in DEO as required. High Mr fractions were obtained by gel 
permeation on PDI0 (Pharmacia) columns prior to freeze drying. All 
experiments were carried out with as fresh plasma s possible which was 
normally used within 24 h of collection. The normal albumin concentra- 
tion in plasma was assumed to be 0.63 mM [1]. 
2.3. pH measurements 
Measurements of pH or pH* (pH meter eading in D20 solutions) 
were made using a Corning 145 pH meter equipped with an Aldrich 
micro combination electrode calibrated with Aldrich pH buffers at pH 
4, 7 and 9. Adjustments of pH were made with microlitre aliquots of 
1.0 M NaOD or DC1. Careful control of pH is very important in this 
work since many His resonances are very sensitive to small pH changes 
in the physiological range. 
2.4. NMR sT)ectroscopy 
600 MHz ~H NMR spectra were recorded at 310 K on Varian 
VXR600 (Biomedical NMR Centre, Mill Hill) or Bruker AMX600 
(ULIRS NMR service, Queen Mary and Westfield College) instru- 
ments, and 500 MHz spectra on a JEOL GSX500 spectrometer (ULIRS 
Biomedical NMR Centre, Birkbeck College), using 0.7 or 0.5 ml of 
sample in 5 mm tubes. Typical conditions: 40-50 ° pulses, spectral width 
12 ppm, 8 K data points, acquisition time 0.5~0.7 s, relaxation delay 
2-2.3 s, 512-1024 transients. For samples in D20, residual HOD was 
suppressed when necessary by presaturation. For samples in 95% H20/ 
5% D20 the WATERGATE sequence [20], which incorporates tailored 
excitation and pulsed-field-gradients, was used to suppress the intense 
solvent resonance. An optimal combination of exponential (1.0 Hz 
line-broadening) and unshifted sine-bell functions [13] was used for 
resolution enhancement and free induction decays were zero-filled once 
before Fourier transformation. Chemical shifts are referenced to so- 
dium 3-(trimethylsilyl)propionate-2,2,3,3-G (TSP) via formate (8.48 
ppm: present in all samples). 
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Fig. 1. 600 MHz IH NMR spectra of the aromatic region of(A) a commercial sample of clinically-used (isolated) human albumin (Armour Albuminar, 
dialyzed, freeze-dried, and reconstituted into deuteriated 10 mM phosphate buffer pH* 7.4) and (B) fresh human blood plasma (freeze-dried, 
reconstituted in the same buffer). Assignments: n, n' Hsl of His 3 of albumin with Cys 34 in blocked and thiolate forms, respectively; a to k, other 
His Hel resonances of albumin; L-Phe, L-Tyr and L-His, free amino acids. Note the high n:n' ratio in (A) compared to (B). 
3. Results 
We have found that reactions at Cys 34 of albumin in blood 
plasma can be detected via observation of ~H NMR resonances 
assignable to His 3. 
3.1. Assignment of His resonances of albumin in spectra of 
plasma 
Many peaks in the aromatic region (6.5 to 9.5 ppm) of a 
typical (resolution-enhanced) IH NMR spectrum of human 
blood plasma are similar to those of isolated albumin, Fig. 1. 
The assignment of peaks to His residues of albumin was 
achieved by pH titrations. Previous tudies on human albumin 
[13,14] and recombinant wild-type and mutant albumins (Chris- 
todoulou, J., Sadler, P.J. and Tucker, A. unpublished) have 
shown that His Hel resonances have characteristic pH titration 
profiles, in particular that for His 3. Similar titration profiles 
were obtained for 10 resonances in the aromatic region of 
spectra of blood plasma, Fig. 2A. Values of pK a were obtained 
from curves fitted to the data, and Fig. 2B shows the excellent 
correlation between the pK, values determined for ten His 
residues of albumin in plasma with those of isolated albumin. 
The assignment for His 3 Hel (pK a 6.42) in the spectrum of 
plasma grees with that based on Ni(II) binding at site VI [15], 
and is supported by the absence of this peak in spectra of 
albumins that lack His 3 (pig, dog [13]), and its perturbation i
spectra of albumin with Asp 1 removed [16]. 
3.2. Drug binding to albumin in blood plasma 
Initially we studied reactions of the antiarthritic gold drugs 
aurothiomalate (Myocrisin) and auranofin (Ridaura) with 
fresh plasma reconstituted in deuteriated buffer. Albumin is 
known to carry more than 70% of the circulating old in pa- 
tients treated with these drugs [I 7], and the major binding site 
for gold(I) on albumin is known to be Cys 34 [18]. Addition of 
either auranofin, or aurothiomalate (data not shown), to blood 
plasma at pH* 7.4, appeared to give rise to a quantitative 
conversion of His 3 Hel peak n' into peak n, Fig. 3. 
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Scheme 1. 
[n contrast, addition of one mol equivalent of auranofin 
(x~ ith respect to albumin) to blood plasma t pH* 6.1 produced 
01dy a ca. 50% switch in n' to n intensities. It is also notable that 
th,~ spectrum of plasma alone shown in Fig. 3 shows no evi- 
dence of peak n (suggesting that the blocked form of albumin 
is not present, vide infra). 
rhe same structural switch involving His 3 of albumin in 
bl.)od plasma was also observed when disulfides were added. 
T?~ese can block Cys 34 via interchange r actions: 
A b-Cys34-S  + RSSR = AIb-Cys34-S-S-R + RS- 
Addition of the drug disulfiram (Antabuse) to plasma caused 
a ~apid and quantitative switch of Hel peak of His 3 from n' to 
n consistent with formation of blocked albumin and release of 
di~;thyldithiocarbamate (reduced rug): 
~ [--- HIs3(n) ,, S 
AIb-S" + Et=NC-S~S- -CNEt= ~ AIb-S-S-CNEt 2 + Et2NC-S" 
L'HIs3(n') Dlsulflram 
Scheme 2. 
Similarly addition of the disulfide L-cystine (0.5 and 1 mol 
e~ aiv with respect o albumin) to plasma lso gave rise to the 
Hs 3 n' to n peak switch (data not shown), consistent with 
formation of'Cys-blocked' albumin (Alb-'Cys34'-S-S-Cys), and 
fr.~e L-Cys. This was very clearly detectable from both the Hel 
al~d H82 peaks of His 3. Interestingly addition of similar 
a]aounts of either glutathione disulfide or n-penicillamine disul- 
rice, the primary metabolite ofthe drug D-penicillamine, did not 
ca use the His 3 structural switch after incubation i  plasma for 
se rural hours at 310 K. We also studied in detail reactions of 
L- :ystine with the high Mr (>5 kDa) fraction of plasma since 
spectra are simpler, avoiding overlap of albumin peaks with 
those of low Mr molecules. Again peak n for His 3 Hel was 
absent in the initial spectrum and only peak n' was seen, but 
peak n appeared after reaction with added L-cystine. The latter 
peak also appeared in the spectrum of the control sample left 
at ambient temperature for a day. 
oo2" 
~ jNH3+ 
+Ha N'~1&~V/'s -s" T 
CO 2" 
L-Cystlne 
Scheme 3. 
o 
Captoprll (trans) 
Reversal of disulfide blockage of albumin in plasma was also 
studied. Cys-blocked albumin was generated in blood plasma 
by reaction with L-cystine and the n' ~ n switch was observed. 
Subsequent addition of the antihypertensive thiol drug cap- 
topril (0.5 mol equiv), an inhibitor of angiotensin I-converting 
enzyme, caused a rapid reversal (< minutes within time taken 
to record spectrum) of the His 3 structural switch. 
All of the above NMR experiments were carried out with 
fresh blood plasma which had been freeze-dried, reconstituted 
in D20 and preconcentrated by a factor of two to allow acqui- 
sition of ~H NMR spectra with signal-to-noise ratios good 
enough for resolution enhancement within a reasonable period 
of time. This procedure also simplifies data acquisition by sup- 
pression of the intense H20 peak and spectral overlap in the 
aromatic region by removal of NH resonances [19]. However, 
we were also able to show that experiments can be carried out 
on intact plasma without hese pretreatment steps using water 
suppression via a combination of tailored excitation and 
pulsed-magnetic-field gradients (WATERGATE [20]). On ac- 
count of the low concentration of albumin, longer spectral 
accumulation times (ca. 1 h) are needed. Similar results are 
obtained, as shown by the disulfiram-induced n' --* n switch 
illustrated in Fig. 4. These data show that our deuteriation 
procedures did not introduce artifacts. 
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- - - I - - -  f 
7.8 ---~--h 
7.6 ~J  
7.4 55 6 65 7 75s3n 'H i  8 85 
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E 
m u 
v,= 
7.5 
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I r I I I 
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F] ~. 2. Determination f pKa values for His residues of albumin and L-His in blood plasma. (A) Variation of chemical shifts of His Hel resonances 
wi ~h pH*. The pK, values, limiting chemical shifts (t~g, ~;HA), and Hill coefficients (n) were extracted from the fitted curves using one of three functions: 
(i) 6obs = (([H+] "' 5HA)+(K]" 6A))/([H+]" + K~) for complete data (ii) 6obs = (([H+] "' (t~A+0.9)) + (K~" 6A))/([H+]" +K.:) for data incomplete atlow pH*, 
and (iii) 6oh, = (([H+]n'~HA) + (Ks  n' (t~nA-0.9)))/([H+]"  KT) for data incomplete athigh pH*. (B) Plot of pKa values of His residues for isolated human 
albumin, calculated from reported ata [12] using the fitting procedure described above, versus those determined for plasma. The gradient is 1.00, 
correlation coefficient 0.996, and intercept of -0.28, the latter presumably arising from differences in ionic strength and temperature of the 
measurements. The pK, for L-His in plasma was determined tobe 6.18. 
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Fig. 3. 600 MHz ~H NMR spectra of the His3 Hel region of human 
blood plasma pH* 7.4. (A) Normal plasma in D20. (B) Plus 0.4 mol 
equiv (with respect to albumin) of the oral antiarthritic drug auranofin. 
The n' ~ n switch was complete with ca. 1 mol equiv of added auran- 
ofin (not shown). Auranofin reacts with Cys 34 to form Alb-'Cys34'-S - 
Au-PEt 3. The same n' ~ n switch is seen when Cys 34 is oxidized, e.g. 
formation of a disulfide with L-cystine. It can therefore be concluded 
that there is little blocked Cys 34 present in fresh plasma. 
4. D iscuss ion  
On the basis of the data presented above for both Au(I) 
binding to albumin in plasma and for disulfide interchange 
reactions, it is clear that little (< 10%) of the albumin in normal 
fresh plasma is present in the structurally-switched (n) form 
which is characteristic of the blocking of Cys 34. This is clear 
from the spectrum of normal plasma shown in Fig. 3A which 
lacks peak n for His 3. In contrast, peak n is readily detected 
when Cys-blocked albumin is artificially generated in plasma 
by addition of cystine. Hence we conclude that Cys34-blocked 
albumin which is commonly present in isolated albumin sam- 
ples at a level of 30-50% of the albumin concentration is likely 
to be an artifact of the isolation procedure. This level of blocked 
Cys 34 in isolated commercial lbumin is evident from the spec- 
trum shown in Fig. 1A where the n:n '  peak ratio is ca. 0.4 
(blocked): 0.6 (unblocked). 
As glutathione disulfide did not react with albumin in blood 
plasma it seems unlikely that high levels of glutathione-blocked 
albumin occur in normal plasma, and we have not detected this 
derivative in isolated albumin by NMR [13,21]. Indeed the level 
of glutathione-blocking  bovine albumin reported by An- 
dersson [22] is < ca. 10% of that of Cys-blocking. Also King 
has reported (briefly) that reactions of human albumin with 
glutathione do not go to completion [23]. Interactions between 
ionic charges may control entry into the Cys 3a crevice, in partic- 
ular reactions with negatively-charged substrates appear to be 
less facile, for example we find with isolated human albumin 
that iodoacetate r acts much less readily than does iodoacet- 
amide, and that aurothiomalate does not react at all at low ionic 
strength (Christodoulou, J., Sadler, P.J. and Tucker, A. unpub- 
lished). 
The anti-hypertensive drug captopril reduced Cys-blocked 
albumin which had been artificially generated in blood plasma 
by prior reaction with cystine and reversed the structural tran- 
sition detectable via His 3. Keire et al. [24] have reported that 
captopril binds to lactate sites on albumin in plasma but does 
not undergo redox reactions. This further supports our sugges- 
tion that little of the albumin in normal plasma is present as a 
mixed disulfide. 
The pH dependence of the extent of reaction of auranofin 
with albumin in blood plasma can be explained by the partial 
protonation of Cys 34 at low pH and the expected lower reactiv- 
ity of Au(I) to towards thiols compared to thiolates [25]. This 
behavior is similar to that which we have observed previously 
for isolated albumin [21,26] and provides further evidence for 
the low pK a associated with the thiol group of Cys 34. 
The reaction of disulfiram with albumin in blood plasma as 
(B) (C) (D) 
PLASMA +0.3 DISULFIRAM +0.6 DISULFIRAM 
n" rl n"  n n"  
\ 
I I I 1 
7.8 7.7 7.8 7.7 7.8 7.7 
(A) L-His His3 n" tll . . . . . .  
I I i 
ppm 8.0 7.0 6.0 
Fig. 4. 600 MHz ~H NMR spectrum of (A) the aromatic region of fresh 
human blood plasma, together with expansions ofthe His 3 Hel region, 
(B) before, (C) after addition of ca. 0.3 and (D) a total of ca. 0.6 mol 
equiv of disulfiram (with respect to albumin). The only treatment tothis 
sample involved the addition of a small amount of phosphate inD~O 
as a lock and buffer (total 5% v/v, 10 mM phosphate). The H20 peak 
was suppressed using the WATERGATE sequence [20]; if presatura- 
tion is used to suppress H20, then albumin also readily saturates by 
cross relaxation [19], although this effect can be used to aid assignment 
of low M r (e.g. L-His) peaks. 
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3 / ~  Auranof|n 
N~, f  ~ ' -  h l  h l  
Cys34 Buried Cys34 Exposed 
Fig. 5. Model for structural changes in domain IA of albumin. In the 
X- ray structure of human albumin with Cys 34 in the thiolate form [4] 
C? s 34 is in a crevice on the inside of a solvent-exposed unstructured 
lo,,p. It is proposed that gold binding (shown), or oxidation to form a 
di,ulfide at Cys 34, or a sulfenic acid, leads to the movement of Cys 34 
fr, m a buried to an exposed environment. This appears to be coupled 
to a movement of His 3 which is part of the N-terminal metal-binding 
si~ : VI of albumin. 
observed via the n' ~ n switch confirms the postulated binding 
oi disulfiram to Cys 34 of albumin in plasma based on 14C and 
35~; labeling [27,28]. In addition the disulfide interchange at 
C ' s  34 explains the rapid disappearance of the administered 
di~ulfiram in vivo and appearance of its metabolite dieth- 
yldithiocarbamate. 
Fig. 5 shows a model for the N-terminal region of albumin 
wtlich is consistent with our observations. In the X-ray struc- 
ture, Cys 34 is situated on a loop of about 4 amino acids between 
helices h2 and h3 in domain IA and is protected from solvent 
in a crevice [5]. We propose that gold binding to Cys 34 or 
o~idation to a disulfide is coupled to a structural change in the 
protein which is sensed by His 3. This might occur via cis-trans 
is, ,merization of Pro 35 and movement of the intervening helices. 
V~e noted previously [21] for isolated albumin that the PEt3 
re:~onances of Alb-'Cys34'-S-Au-PEt3 are well-resolved, show- 
ing that this group is highly mobile on the protein and therefore 
lil, ely to be in an exposed rather than in a buried environment. 
If these reactions involve a Cys 34 'flip-out', then they may in- 
w lye large activation energies. Indeed Roberts et al. [29] have 
re:~orted that the reaction of auranofin with bovine albumin is 
re atively slow (k~ = 2.94 x 10 -2 s-~). It is first order with respect 
te albumin but zero order with respect o auranofin, consistent 
w~th crevice-opening and exposure of Cys 34 being the rate- 
livliting process. 
Our observations help to explain the plethora of observa- 
ti,.ns on albumin heterogeneity. The presence of low amounts 
or Cys34-blocked albumin in fresh plasma is consistent with 
5.7-thiobis(2-nitrobenzoic a id) titrations of fresh blood 
plasma which show that the total thiol level is similar to the 
c¢,ncentration of albumin [30], whereas the SH content of 
plasma stored for up to 6 weeks at -80°C [31] and isolated 
albumin [22] are typically only ca. 50-70% of the albumin level. 
The NMR method described here has the advantage of allow- 
in;  direct and specific monitoring of structural changes at Cys 34 
oJ albumin in plasma. In isolated albumin the major crevice- 
ol,ened forms are likely to be the Cys-blocked disulfide and 
AIb-'Cys34'-SOx H [32,18]. The disulfide but not all the sulfenic 
at id forms are readily reduced to the free thiolate with added 
th~ols, a behavior analogous to that of Cys 25 of papain [33]. It 
is likely that there are mechanisms for maintaining Cys 34 of 
albumin in the free thiolate form in blood. 
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